跳到正文
原文
Medical Xpress·· 2026-10-13AI 评分46

日本长期肝炎控制与肝癌死亡率变化模式

Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan

AI 导读

研究团队在《The Lancet Regional Health—Western Pacific》发表论文,分析了日本自1958年至2022年肝炎控制措施对肝癌死亡率的影响,HBV和HCV感染率显著下降,肝癌死亡率减少,非病毒性肝癌比例增加。

正文
Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan
Long-term trends in cancer-specific mortality in Japan between 1958 and 2022, by sex. Credit: Junko Tanaka, et al. The Lancet Regional Health - Western Pacific. August 17, 2026

Over decades of sustained, integrated national viral hepatitis control, Japan has seen substantial reductions in HBV- and HCV-related disease burden and hepatocellular carcinoma mortality.

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of liver cirrhosis and hepatocellular carcinoma (HCC). Due to the public health burden of viral hepatitis, Japan enacted systematic, nationwide countermeasures, starting with improvements in blood safety and reductions in health care-associated transmission (from the 1970s onward); prevention of mother-to-child transmission (from 1986 onward); and institutionalization of hepatitis control through legal and financial frameworks and expanded access to antiviral treatment (from the 2000s onward).

A review paper by a research team at Hiroshima University investigated how coordinated policy frameworks and robust epidemiological infrastructure have been associated with reductions in viral hepatitis–related HCC in Japan and what gaps remain toward achieving hepatitis elimination. In doing so, they highlight transferable lessons for countries seeking to eliminate viral hepatitis.

The review was published in the journal The Lancet Regional Health—Western Pacific.

Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan
Estimated number of individuals living with chronic hepatitis B virus (orange) and hepatitis C virus (blue) infection in Japan between 2000 and 2020, with projected future trends to 2050. Credit: Junko Tanaka, et al. The Lancet Regional Health—Western Pacific. August 17, 2026

"This study examines how the epidemiology of viral hepatitis and liver cancer in Japan has changed over nearly five decades of national hepatitis control measures, and what challenges remain as the country approaches the WHO 2030 hepatitis elimination targets," says Tomoyuki Akita, a lecturer at Hiroshima University's Graduate School of Biomedical and Health Sciences.

"Understanding the long-term population impact of [Japan's viral hepatitis control] measures is important not only for evaluating Japan's progress toward hepatitis elimination, but also for identifying the next priorities for liver cancer prevention."

The researchers collected peer-reviewed research articles related to HCC, liver cancer, viral hepatitis, liver cirrhosis and Japan, published between January 1970 and January 2026, through online searches of the PubMed database.

They also manually searched government reports for additional sources, included data from their Epidemiological Research Group on Viral Hepatitis and its Long-term Course (VH-Epi), and incorporated data from national vital statistics and multiple large-scale statistics and surveillance databases.

Decades of hepatitis control have brought Japan closer to elimination

The prevalence of HBV and HCV has fallen drastically across Japan. In first-time blood donors—generally considered a healthy population—the prevalence of hepatitis B surface antigen (HBsAg, a positive marker of HBV infection) fell from 0.63% in 1995–2000 to 0.13% in 2017–2021; the prevalence of HCV antibody (anti-HCV, a positive marker of HCV infection) fell from 0.49% to 0.16% over the same periods.

Among residents aged ≥40 years at health checkups, HBsAg prevalence fell from 1.16% in 2002 to 0.55% in 2021, while anti-HCV prevalence fell from 1.16% to 0.21% in the same period. The incidence of newly acquired HBV and HCV infections in blood donors was at historically low levels in Japan, at 2.38 per 100,000 person-years for HBV and 0.4 per 100,000 person-years for HCV.

Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan
Temporal changes in total hepatocellular carcinoma (HCC) mortality and mortality associated with HBsAg-positive, HCVAb-positive, HBsAg-negative, and non-B non-C (NBNC) liver disease. Credit: Junko Tanaka, et al. The Lancet Regional Health—Western Pacific. August 17, 2026

"One particularly striking finding is that among pregnant women born in or after 2000, HBsAg-positive individuals have become extremely rare, illustrating the intergenerational impact of Japan's HBV mother-to-child transmission prevention program since 1986," says Akita.

Viral hepatitis remains an important concern among several high-risk populations in Japan, including persons who inject drugs (PWID), men who have sex with men (MSM), migrants from regions where HBV is endemic and incarcerated populations. Addressing viral hepatitis among these populations remains an important challenge as Japan moves toward elimination.

At the same time, the decline in viral hepatitis–related HCC has reshaped the relative distribution of liver cancer causes in Japan. The proportion of HCC deaths attributed to nonviral causes increased from 6.8% in 1992 to 56.0% in 2019.

This shift largely reflects the substantial decline in viral hepatitis–related HCC, rather than a comparable increase in the absolute burden of nonviral HCC. "In other words," Akita says, "more than half of hepatocellular carcinoma deaths in Japan are now attributable to nonviral causes—a dramatic reversal from the era when viral hepatitis dominated the country's liver cancer burden."

Nonviral causes include alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease (MASLD). As Japan approaches viral hepatitis elimination, maintaining the achievements of hepatitis control remains essential, while liver cancer prevention will also need to address these emerging nonviral causes.

"Japan's long-term, integrated hepatitis control strategy has substantially reduced HBV and HCV infections and related liver cancer deaths, bringing the country closer to hepatitis elimination," Akita says. "The next step is to achieve and sustain viral hepatitis elimination while adapting liver cancer prevention to Japan's changing disease landscape."

More information

Junko Tanaka et al., Liver cancer in Japan: epidemiological transition, viral hepatitis control, and emerging challenges, The Lancet Regional Health - Western Pacific (2026). DOI: 10.1016/j.lanwpc.2026.101900

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-term-viral-hepatitis-patterns-liver.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com